Clinical trial NCT01384799: Phase I Study of CUDC-101 With Cisplatin and Radiation in Subjects With Head & Neck Cancer
Official title: A Phase I Dose Escalation Study to Investigate the Safety and Pharmacokinetics of Intravenous CUDC-101 With Concurrent Cisplatin and Radiation Therapy in Subjects With Locally Advanced Head and Neck Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Head and Neck Cancer
Lead sponsor: Curis, Inc.
Sponsor class: INDUSTRY
First posted: 2011-06-29
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a phase I dose escalation study of CUDC-101 in combination with concurrent cisplatin and radiation therapy in patients with locally advanced head and neck cancer. CUDC-101 is a multi-targeted agent designed to inhibit epidermal growth factor receptor (EGFR), human epidermal growth factor receptor Type 2 (Her2) and histone deacetylase (HDAC). The study is designed to establish the safety, tolerability and maximum tolerated dose (MTD) of CUDC-101 when administered in combination with concurrent cisplatin and radiation over an 8-week treatment course, consisting of a one week run-in period of CUDC-101 administered alone, followed by seven weeks of combination treatment with CUDC-101, cisplatin and radiation therapy.


Eligibility criteria: Inclusion Criteria:

* Subjects with locally advanced, pathologically confirmed diagnosis of squamous cell carcinoma of the head and neck at the following sites: oral cavity, oropharynx, hypopharynx and larynx with either:

  * Stage IV p16 positive tumors and \>10 pack-years smoking history.
  * Stage III/IV p16 negative tumors, regardless of smoking history.
* At least evaluable disease; one measurable site of disease according to RECIST (Version 1.1) criteria (at least 10 mm for conventional CT/MRI or spiral CT scan) is desirable.
* Subjects enrolled in the MTD expansion cohort must have at least 1 tumor lesion that is suitable for repeat biopsy (pre- and post-CUDC-101 infusion).
* Age ≥ 18 years
* ECOG performance \< 2
* Life expectancy ≥ 3 months
* If female, neither pregnant nor lactating
* If of child bearing potential, must use adequate birth control throughout the participation in the treatment phase and for 60 days following the last study treatment.
* Absolute neutrophil count ≥ 1,800/µL; platelets ≥ 100,000/µL; hemoglobin ≥ 8.0 g/dL, creatinine ≤ 1.5x upper limit of normal (ULN); total bilirubin ≤ 1.5x ULN; AST/ALT ≤ 2 x ULN.
* Serum magnesium and potassium within normal limits (may be supplemented to achieve normal values)
* Able to render informed consent and to follow protocol requirements.

Exclusion Criteria:

* Prior radiotherapy to the region of the study cancer or adjacent anatomical sites, or \> 25% of marrow-bearing area.
* Prior chemotherapy for the current indication.
* Prior therapy that specifically and directly targets EGFR, HER2 or HDAC.
* Use of investigational agent(s) within 30 days prior to study treatment.
* Primary tumor site of nasopharynx, sinuses, or salivary gland.
* History of cardiac disease with a New York Heart Association (NYHA) Class II or greater congestive heart failure (CHF), myocardial infarction (MI) or unstable angina in the past 6 months prior to Day 1 of treatment, serious arrhythmias requiring medication for treatment.
* Patients with prolonged QTc Interval \>450 msec.
* Acquired Immune Deficiency Syndrome (AIDS) or known infection with human immunodeficiency virus (HIV). Testing is not required.
* Known history of gastrointestinal bleeding, ulceration, or perforation within 6 months prior to study treatment.
* Known history of stroke or cerebrovascular accident within 6 months prior to study treatment.
* Symptomatic cardiac conduction abnormality within 12 months prior to study treatment.
* Prior history of hearing impairment.
* Known history of renal disease or ongoing renal impairment.
* Any uncontrolled condition (such as active systemic infection, diabetes, hypertension), which in the opinion of the investigator, could affect the subjects participation in the study.
* Prior allergic reaction to cisplatin, carboplatin or other platinum-containing compounds.
* Central nervous system metastases.

Primary outcomes:
measure: The number of participants with adverse events.
timeFrame: 18-24 months
Secondary outcomes:
measure: The number of subjects disease free at the completion of the treatment period.
timeFrame: 18-24 months
measure: The number of subjects disease free in the follow up period.
timeFrame: 18-24 months
measure: Concentration of CUDC-101 in the blood over time.
timeFrame: 18-24 months
measure: Number of circulating tumor cells pre treatment on Day -7 and 1 hour post treatment on Day -3.
timeFrame: 18-24 months
Other outcomes:
Locations:
city: Stanford
country: United States
facility: Stanford Cancer Center
state: California
city: Aurora
country: United States
facility: University of Colorado Cancer Center
state: Colorado
city: Shreveport
country: United States
facility: Overton Brooks VA Medical Center
state: Louisiana
city: Boston
country: United States
facility: Massachusetts General Hospital
state: Massachusetts
city: Detroit
country: United States
facility: Henry Ford Health System
state: Michigan
city: Philadelphia
country: United States
facility: Fox Chase Cancer Center
state: Pennsylvania
city: Nashville
country: United States
facility: Vanderbilt University
state: Tennessee
Study officials:
References: